GR72534B - - Google Patents

Info

Publication number
GR72534B
GR72534B GR63671A GR800163671A GR72534B GR 72534 B GR72534 B GR 72534B GR 63671 A GR63671 A GR 63671A GR 800163671 A GR800163671 A GR 800163671A GR 72534 B GR72534 B GR 72534B
Authority
GR
Greece
Application number
GR63671A
Other languages
Greek (el)
Inventor
Rudi Weyer
Volker Hitzel
Karl Geisen
Gunter Regitz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of GR72534B publication Critical patent/GR72534B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR63671A 1979-12-19 1980-12-17 GR72534B (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792951135 DE2951135A1 (de) 1979-12-19 1979-12-19 Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung

Publications (1)

Publication Number Publication Date
GR72534B true GR72534B (cg-RX-API-DMAC10.html) 1983-11-17

Family

ID=6088937

Family Applications (1)

Application Number Title Priority Date Filing Date
GR63671A GR72534B (cg-RX-API-DMAC10.html) 1979-12-19 1980-12-17

Country Status (21)

Country Link
US (1) US4379785A (cg-RX-API-DMAC10.html)
EP (1) EP0031058B1 (cg-RX-API-DMAC10.html)
JP (1) JPS56108762A (cg-RX-API-DMAC10.html)
AR (3) AR240922A1 (cg-RX-API-DMAC10.html)
AT (1) ATE6934T1 (cg-RX-API-DMAC10.html)
AU (1) AU538129B2 (cg-RX-API-DMAC10.html)
CA (1) CA1167033A (cg-RX-API-DMAC10.html)
DE (2) DE2951135A1 (cg-RX-API-DMAC10.html)
DK (1) DK156434C (cg-RX-API-DMAC10.html)
ES (6) ES497661A0 (cg-RX-API-DMAC10.html)
FI (1) FI75338C (cg-RX-API-DMAC10.html)
GR (1) GR72534B (cg-RX-API-DMAC10.html)
HU (1) HU184943B (cg-RX-API-DMAC10.html)
IE (1) IE50635B1 (cg-RX-API-DMAC10.html)
IL (1) IL61733A (cg-RX-API-DMAC10.html)
LU (1) LU90244I2 (cg-RX-API-DMAC10.html)
MX (4) MX174496B (cg-RX-API-DMAC10.html)
NL (1) NL950026I2 (cg-RX-API-DMAC10.html)
NO (2) NO155290C (cg-RX-API-DMAC10.html)
PT (1) PT72226B (cg-RX-API-DMAC10.html)
ZA (1) ZA807911B (cg-RX-API-DMAC10.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4985417A (en) * 1989-05-02 1991-01-15 Trager Seymour F Treatment of glaucoma
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
US5631275A (en) * 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
CA2320900C (en) 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
MXPA03001157A (es) * 2000-08-07 2004-02-17 Ranbaxy Signature Llc Formulacion liquida de metformina.
PE20020617A1 (es) 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
AU2003235814A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
JP2006516620A (ja) * 2003-01-24 2006-07-06 ブリストル−マイヤーズ　スクイブ　カンパニー 甲状腺受容体におけるシクロアルキル含有アニリドリガンド
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CZ293789B6 (cs) * 2003-02-21 2004-07-14 Zentiva, A.S. Způsob výroby glimepiridu a příslušný meziprodukt
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
KR100712234B1 (ko) * 2003-08-08 2007-04-27 명문제약주식회사 글리메피라이드의 제조방법
KR101152729B1 (ko) 2003-09-17 2012-06-15 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 메카니즘-기초 표적화된 췌장 베타 세포 영상화 및 치료법
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1743676A1 (en) 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2006017292A1 (en) * 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US7238702B2 (en) * 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
EP1700848A1 (en) * 2005-03-11 2006-09-13 IPCA Laboratories Limited Method for the Manufacture of Compounds Related to the Class of Substituted Sulphonyl Urea Anti-Diabetics
KR20070116778A (ko) * 2005-04-01 2007-12-11 유에스브이 리미티드 실질적으로 순수한 글리메피리드의 신규한 제조방법
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7572808B2 (en) * 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2007016353A2 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CN101092402B (zh) * 2006-06-23 2012-02-08 唐仲雄 磺酰脲类化合物及其医药用途
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US20090076125A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched glimepiride
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
HRP20240365T1 (hr) * 2009-02-13 2024-06-07 Boehringer Ingelheim International Gmbh Farmaceutski pripravak koji sadrži derivate glukopiranozil difenilmetana, njegov farmaceutski oblik za doziranje, postupak za njihovu proizvodnju i njihove uporabe za poboljšanu regulaciju glikemije kod pacijenta
MX344264B (es) 2009-02-13 2016-12-09 Boehringer Ingelheim Int Gmbh * Inhibidor de sglt-2 para el tratamiento de diabetes mellitus tipo 1, diabetes mellitus tipo 2, tolerancia deteriorada a la glucosa o hiperglucemia.
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
EP2430018B1 (en) 2009-05-15 2013-07-03 Novartis AG Benzoxazolone derivatives as aldosterone symthase inhibitors
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
AU2010303123B2 (en) 2009-09-30 2014-02-27 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
HUE026133T2 (en) 2009-09-30 2016-05-30 Boehringer Ingelheim Int Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
ES2551002T3 (es) 2009-11-17 2015-11-13 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
US10940159B2 (en) 2010-07-09 2021-03-09 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2014230444B2 (en) 2013-03-15 2018-05-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
HK1215398A1 (zh) 2013-04-05 2016-08-26 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2986304T (pt) 2013-04-18 2022-02-25 Boehringer Ingelheim Int Composição farmacêutica, métodos para o tratamento e suas utilizações
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
CN103288703B (zh) * 2013-06-09 2015-10-21 南通市华峰化工有限责任公司 Ⅱ型糖尿病药物格列美脲中间体苯磺酰胺的合成方法
CN103420891B (zh) * 2013-06-09 2015-10-21 南通市华峰化工有限责任公司 Ⅱ型糖尿病药物格列美脲中间体苯磺胺三光气的合成方法
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EA201790526A1 (ru) 2014-09-05 2017-06-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации ситаглиптина
EP3009422A1 (en) * 2014-10-14 2016-04-20 Ludwig-Maximilians-Universität München Photo-switchable sulfonylureas and their uses
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN108383768A (zh) * 2018-04-13 2018-08-10 江西博雅欣和制药有限公司 一种格列美脲原料药合成工艺
CN112028807A (zh) * 2020-08-07 2020-12-04 重庆康刻尔制药股份有限公司 一种格列美脲原料药的精制方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670700U (de) 1952-11-12 1954-01-21 Siemens Ag Aufhaengevorrichtung fuer pendelleuchten.
DE1198354B (de) * 1963-09-25 1965-08-12 Hoechst Ag Verfahren zur Herstellung von Benzol-sulfonylharnstoffen
LU47776A1 (cg-RX-API-DMAC10.html) * 1964-07-30 1966-07-13
DE1445774A1 (de) * 1964-07-30 1969-01-23 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1443911C3 (de) * 1964-12-08 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE1670700B2 (de) * 1966-05-14 1978-06-22 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US3646009A (en) * 1967-03-15 1972-02-29 Boehringer & Soehne Gmbh Anti-diabetically active sulfonyl-semicarbazides
US3819633A (en) * 1970-04-01 1974-06-25 Erba Carlo Spa (iso)quinolyl sulfonylureas having antidiabetic activity
DE2103118A1 (en) * 1971-01-23 1972-08-24 Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt 4 (2-heterocyclylethyl) - benzenesulphonylureas - with hypoglycaemic activity
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
DE2238870C3 (de) * 1972-08-07 1978-09-28 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe
DE2621958A1 (de) * 1976-05-18 1977-12-08 Hoechst Ag Benzolsulfonylharnstoffe und verfahren zu ihrer herstellung
MTP848B (en) * 1978-06-27 1980-06-24 Hoechst Ag Sulfonyl ureas process for their manufacture pharmaceutical preparation on the basis of there compounds and their use

Also Published As

Publication number Publication date
ES498228A0 (es) 1982-02-01
US4379785A (en) 1983-04-12
ATE6934T1 (de) 1984-04-15
NO1996009I1 (no) 1996-07-30
NL950026I1 (cg-RX-API-DMAC10.html) 1996-01-02
ES8200665A1 (es) 1981-11-01
MX8254A (es) 1993-04-01
ZA807911B (en) 1981-12-30
MX6926E (es) 1986-12-01
ES498224A0 (es) 1982-02-01
EP0031058A1 (de) 1981-07-01
PT72226A (de) 1981-01-01
IE50635B1 (en) 1986-05-28
DE3067390D1 (en) 1984-05-10
AR240922A1 (es) 1991-03-27
ES8202542A1 (es) 1982-02-01
JPH0139424B2 (cg-RX-API-DMAC10.html) 1989-08-21
NO155290B (no) 1986-12-01
NL950026I2 (nl) 1997-01-06
DE2951135A1 (de) 1981-06-25
DK156434C (da) 1990-01-22
FI803937L (fi) 1981-06-20
IL61733A (en) 1985-05-31
AR240922A2 (es) 1991-03-27
LU90244I2 (fr) 1998-07-20
AR230989A1 (es) 1984-08-31
IE802676L (en) 1981-06-19
AU538129B2 (en) 1984-08-02
DK156434B (da) 1989-08-21
ES497661A0 (es) 1981-11-01
IL61733A0 (en) 1981-01-30
HU184943B (en) 1984-11-28
AR231131A1 (es) 1984-09-28
FI75338B (fi) 1988-02-29
MX8352A (es) 1993-11-01
EP0031058B1 (de) 1984-04-04
ES8202798A1 (es) 1982-03-01
ES8202541A1 (es) 1982-02-01
ES498227A0 (es) 1982-02-01
FI75338C (fi) 1988-06-09
ES8202799A1 (es) 1982-03-01
AU6552380A (en) 1981-06-25
ES498226A0 (es) 1982-03-01
DK540280A (da) 1981-06-20
NO155290C (no) 1987-03-11
PT72226B (de) 1982-03-26
MX174496B (es) 1994-05-19
ES8202543A1 (es) 1982-02-01
JPS56108762A (en) 1981-08-28
ES498225A0 (es) 1982-03-01
CA1167033A (en) 1984-05-08
NO803855L (no) 1981-06-22

Similar Documents

Publication Publication Date Title
FR2447163B3 (cg-RX-API-DMAC10.html)
FR2449655B1 (cg-RX-API-DMAC10.html)
GR72534B (cg-RX-API-DMAC10.html)
BR8002583A (cg-RX-API-DMAC10.html)
BR8006808A (cg-RX-API-DMAC10.html)
FR2448909B1 (cg-RX-API-DMAC10.html)
FR2449502B1 (cg-RX-API-DMAC10.html)
FR2447851B3 (cg-RX-API-DMAC10.html)
FR2447496B1 (cg-RX-API-DMAC10.html)
FR2448375B1 (cg-RX-API-DMAC10.html)
DE2909272C2 (cg-RX-API-DMAC10.html)
FR2449851B1 (cg-RX-API-DMAC10.html)
FR2447294B1 (cg-RX-API-DMAC10.html)
FR2447673B1 (cg-RX-API-DMAC10.html)
FR2445771B2 (cg-RX-API-DMAC10.html)
FR2450198B1 (cg-RX-API-DMAC10.html)
FR2445708B1 (cg-RX-API-DMAC10.html)
AU78390S (cg-RX-API-DMAC10.html)
AU78386S (cg-RX-API-DMAC10.html)
AU79557S (cg-RX-API-DMAC10.html)
AU79200S (cg-RX-API-DMAC10.html)
AU79559S (cg-RX-API-DMAC10.html)
AU79826S (cg-RX-API-DMAC10.html)
AU79918S (cg-RX-API-DMAC10.html)
AU80228S (cg-RX-API-DMAC10.html)